Mutations in BRCA1/2 genes, especially germline variations, along with other Fanconi anaemia (FA) pathway genes (such as NBN, RAD54L, ATM), are prototypic molecular alterations that confer HRD in breast cancer [8]. This evidence concerns the gene BRCA1 and Fanconi anemia.